Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2021
December 2021, Vol 12, No 6
December 2021, Vol 12, No 6
AVBCC Panel Explores Value-Based Contracting in Oncology Care
AVBCC 2021 Summit
December 2021, Vol 12, No 6
At the 11th Annual Summit of the Association for Value-Based Cancer Care (AVBCC) in 2021, health plans and employers discussed the utility of value-based contracting for managing oncology care costs while maintaining focus on outcomes of value for patients.
Read More
Future-Proofing Cancer Care Against Pandemics
By
William King
AVBCC 2021 Summit
December 2021, Vol 12, No 6
Enhanced flexibility in delivery, increased investment in digital capability, and quick adaptation to events were some of the positive impacts of the COVID-19 pandemic on cancer care.
Read More
Drug Price Reform with Value in Mind: Is It Possible?
By
Wayne Kuznar
AVBCC 2021 Summit
December 2021, Vol 12, No 6
Oncologic drug pricing is being transformed with greater value in mind. At the 11th Annual Summit of the Association for Value-Based Cancer Care in 2021, a panel led by moderator William McGivney, PhD, Managing Principal, McGivney Global Advisors, Wayne, PA, discussed innovation in drug pricing, how the current rebate system supports higher drug costs, balancing new interventions with profits, and the implications of drug price negotiations being considered in Congress.
Read More
The Impact of Telehealth on Quality, Access, and Cost in Cancer Care
By
Wayne Kuznar
AVBCC 2021 Summit
December 2021, Vol 12, No 6
The use of telehealth in the fee-for-service program surged by more than 4000% during the first 6 months of the COVID-19 pandemic.
Read More
Reducing Racial Disparities in Cancer Care
By
William King
AVBCC 2021 Summit
December 2021, Vol 12, No 6
Reducing disparities in cancer care, including those affecting research and treatment, requires a better understanding of the history of racism, noted experts during a panel discussion at the 11th Annual Summit of the Association for Value-Based Cancer Care in 2021. The panel, which was moderated by Sybil Green, JD, RPh, MHA, Diversity and Inclusion Officer, American Society of Clinical Oncology, examined barriers to equitable care and potential solutions to remove these barriers.
Read More
Biosimilars and the Road Ahead
By
Wayne Kuznar
AVBCC 2021 Summit
December 2021, Vol 12, No 6
Currently, 31 biosimilar products have been approved by the FDA, 20 of which have been launched in the United States.
Read More
The Current and Future State of Medically Integrated Pharmacy in Oncology
By
William King
AVBCC 2021 Summit
December 2021, Vol 12, No 6
t the 11th Annual Summit of the Association for Value-Based Cancer Care in 2021, a panel of experts, moderated by Michael Reff, RPh, MBA, Founder and Executive Director, National Community Oncology Dispensing Association (NCODA), Cazenovia, NY, discussed the current and future state of Medically Integrated Pharmacy (MIP) and the benefits of this approach in oncology.
Read More
FDA Approves Scemblix for 2 Indications in CML
FDA Approvals, News & Updates
December 2021, Vol 12, No 6
On October 29, 2021, the FDA granted accelerated approval to asciminib (Scemblix; Novartis) for the treatment of patients with Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, previously treated with ≥2 tyrosine kinase inhibitors.
Read More
Tivdak First Antibody–Drug Conjugate FDA Approved for Recurrent or Metastatic Cervical Cancer
FDA Approvals, News & Updates
December 2021, Vol 12, No 6
On September 20, 2021, the FDA accelerated the approval of tisotumab vedotin-tftv (Tivdak; Seagen), a tissue factor–directed antibody and microtubule inhibitor conjugate, for the treatment of women with recurrent or metastatic cervical cancer whose disease progressed during or after chemotherapy.
Read More
Tecentriq Approved for Adjuvant Treatment of Patients with Early-Stage NSCLC and PD-L1 Expression
FDA Approvals, News & Updates
December 2021, Vol 12, No 6
On October 15, 2021, the FDA approved a new indication for atezolizumab (Tecentriq; Genentech) for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non–small-cell lung cancer (NSCLC) whose tumors have PD-L1 expression on ≥1% of tumor cells, as determined by an FDA-approved test.
Read More
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma